TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Quantum Biopharma ( (TSE:QNTM) ) has shared an update.
On November 7, 2025, Quantum BioPharma Ltd. reported strong financial results for the third quarter ending September 30, 2025, showing significant improvements in shareholder equity and a reduction in liabilities. The company highlighted its continued progress in clinical trials for its multiple sclerosis drug, Lucid-21-302, and the market growth of its alcohol metabolizer product, unbuzzd. With a cash runway extending beyond March 2027, Quantum BioPharma maintains a robust financial position, supporting its strategic initiatives and potential monetization events. The company also announced a partnership with Massachusetts General Hospital for a study on a novel PET imaging technique for monitoring MS, and received a product license from Health Canada for its natural health product, Qlarity.
More about Quantum Biopharma
Quantum BioPharma Ltd. operates in the biopharmaceutical industry, focusing on developing treatments for brain disorders and alcohol health. The company is engaged in advancing clinical trials for its multiple sclerosis drug, Lucid-21-302, and markets a recreational beverage and alcohol metabolizer, unbuzzd. Quantum BioPharma is also involved in cryptocurrency investments and has a presence in the natural health product market with its product Qlarity.
Average Trading Volume: 3,503
Technical Sentiment Signal: Sell
Current Market Cap: C$47.18M
For detailed information about QNTM stock, go to TipRanks’ Stock Analysis page.